MedTrace Logo

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

NCT02728934 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1279

Last updated 2020-04-15

No results posted yet for this study

Summary

The purpose of this study is to compare the proportion of patients with an infusion reaction in Rheumatoid arthritis (RA) patients treated with Golimumab Intravenous (IV) or Infliximab.

Conditions

  • Arthritis, Rheumatoid

Interventions

BIOLOGICAL

Golimumab Intravenous (IV)

This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.

BIOLOGICAL

Infliximab

This is an observational study. Patients who will receive infliximab will be observed for 3 years.

BIOLOGICAL

Biosimilar Infliximab

This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Scientific Affairs, LLC Clinical Trial · Janssen Scientific Affairs, LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-25
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02728934 on ClinicalTrials.gov